| Detailed information |
|---|
| CancerLivER ID | 2547 |
| Biomarker | FBN1, MEF2C, TNFAIP3, LAPTM5, TMSB4X, CUGBP2, HLA-DRA, REL, clone110298, LTBP2, TRIM22, HLA-DRBI, FOXF1, HLA-DQA, SDF1, DDX17, SGK, PDGFRA, F2R, HLADG, MTAP44, CTSK, VIM, ACVR1, ON/SPARC, SCYA3, ARHGEF6, CCND2, COL1A1, ITGB2/CD18, PTPRC, MKNK1, JUNB, EST, GATA6, FUT3, RDBP, E48, SEMA3F, COL6A3, GBAP |
| Biomarker Name/Symbol (given in Publication) | FBN1, MEF2C, TNFAIP3, LAPTM5, TMSB4X, CUGBP2, HLA-DRA, REL, clone110298, LTBP2, TRIM22, HLA-DRBI, FOXF1, HLA-DQA, SDF1, DDX17, SGK, PDGFRA, F2R, HLADG, MTAP44, CTSK, VIM, ACVR1, ON/SPARC, SCYA3, ARHGEF6, CCND2, COL1A1, ITGB2/CD18, PTPRC, MKNK1, JUNB, EST, GATA6, FUT3, RDBP, E48, SEMA3F, COL6A3, GBAP, FUT1, GCHFR, CYP2A, MLH1, EST |
| Biomolecule | RNAs |
| Subject | Human |
| Degree of Validity | Prognostic marker for detection of early intrahepatic recurrence of HCC and validated on independent dataset |
| Experimental Condition | Intrahepatic recurrence v/s Non-recurrence |
| Cancer type | Hepatocellular carcinoma |
| Regulation | 11 genes (FUT3, RDBP, E48, SEMA3F, COL6A3, GBAP, FUT1, GCHFR, CYP2A, MLH1, EST) Upregulated and rest 35 genes downregulated in HCC with early IHR vs. HCC without recurrence |
| Level of significance | p < 0.05 |
| Source | Tissue |
| PMID | 15688398 |
| Type of Biomarker | Prognostic |
| Pathway | Transcription, regulate immune response, cell cycle, apoptosis, metabolic pathways |
| Cohort | Training dataset: 33 HCC patients containing12 HCCs with early IHR (intrahepatic recurrence) and 21 HCCs with nonrecurrence; validation dataset:27 blinded HCC |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | Intrahepatic recurrence v/s Non-recurrence |
| Year of Publication | 2005 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |